ReviewFrontiers in cell and developmental biology2026
Current insights into circulating biomarkers and their potential for predicting adolescent idiopathic scoliosis progression.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Vitamin E-Related Molecular Signatures in Adolescent Idiopathic Scoliosis: A Hypothesis-Generating Multi-Omics Analysis.Food science & nutrition · 2026Article
- Outcomes of high-compliance bracing in patients with severe adolescent idiopathic scoliosis declining operative intervention.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adolescent Idiopathic Scoliosis (AIS) is a three-dimensional deformation of the spine with a frontal plane curvature of 10° or more, measured using Cobb method. It typically gets more severe during pre-puberty and puberty, currently exhibiting unpredictable progression. Severe disease is more prevalent in females, and progression is associated with respiratory and neuromuscular dysfunction, pain, and psychological complications. Management strategies are guided by curve severity and include observation, therapeutic exercises, bracing, and surgery. Despite advances, the cellular and molecular mechanisms driving AIS remain poorly understood. Early detection and reliable progression biomarkers are increasingly recognized as critical to prevent clinical mismanagement. This mini-review summarizes current evidence on circulating biomarkers investigated in AIS, including growth-related hormones, bone metabolism proteins, and more recently non-coding RNAs (ncRNAs) such as microRNAs. In addition, we highlight key methodological limitations and risk-of-bias concerns across existing studies, especially the reliance on single-time-point sampling, underscoring the need for longitudinal prospective cohorts with repeated biomarker measurements. Such designs are critical for capturing dynamic biological changes, distinguishing stable from progressive cases, and validating biomarker trajectories for integration into clinically meaningful prediction models for AIS progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.